Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study
© Dobbs et al.; licensee BioMed Central Ltd. 2012
Received: 3 August 2012
Accepted: 25 September 2012
Published: 19 October 2012
Following Helicobacter pylori eradication in idiopathic parkinsonism (IP), hypokinesia improved but flexor-rigidity increased. Small intestinal bacterial-overgrowth (SIBO) is a candidate driver of the rigidity: hydrogen-breath-test-positivity is common in IP and case histories suggest that Helicobacter keeps SIBO at bay.
In a surveillance study, we explore relationships of IP-facets to peripheral immune/inflammatory-activation, in light of presence/absence of Helicobacter infection (urea-breath- and/or stool-antigen-test: positivity confirmed by gastric-biopsy) and hydrogen-breath-test status for SIBO (positivity: >20 ppm increment, 2 consecutive 15-min readings, within 2h of 25G lactulose). We question whether any relationships found between facets and blood leukocyte subset counts stand in patients free from anti-parkinsonian drugs, and are robust enough to defy fluctuations in performance consequent on short t½ therapy.
Of 51 IP-probands, 36 had current or past Helicobacter infection on entry, 25 having undergone successful eradication (median 3.4 years before). Thirty-four were hydrogen-breath-test-positive initially, 42 at sometime (343 tests) during surveillance (2.8 years). Hydrogen-breath-test-positivity was associated inversely with Helicobacter-positivity (OR 0.20 (95% CI 0.04, 0.99), p<0.05).
In 38 patients (untreated (17) or on stable long-t½ IP-medication), the higher the natural-killer count, the shorter stride, slower gait and greater flexor-rigidity (by mean 49 (14, 85) mm, 54 (3, 104) mm.s-1, 89 (2, 177) Nm.10-3, per 100 cells.μl-1 increment, p=0.007, 0.04 & 0.04 respectively, adjusted for patient characteristics). T-helper count was inversely associated with flexor-rigidity before (p=0.01) and after adjustment for natural-killer count (-36(-63, -10) Nm.10-3 per 100 cells.μl-1, p=0.007). Neutrophil count was inversely associated with tremor (visual analogue scale, p=0.01). Effect-sizes were independent of IP-medication, and not masked by including 13 patients receiving levodopa (except natural-killer count on flexor-rigidity). Cellular associations held after allowing for potentially confounding effect of hydrogen-breath-test or Helicobacter status. Moreover, additional reduction in stride and speed (68 (24, 112) mm & 103 (38, 168) mm.s-1, each p=0.002) was seen with Helicobacter-positivity. Hydrogen-breath-test-positivity, itself, was associated with higher natural-killer and T-helper counts, lower neutrophils (p=0.005, 0.02 & 0.008).
We propose a rigidity-associated subordinate pathway, flagged by a higher natural-killer count, tempered by a higher T-helper, against which Helicobacter protects by keeping SIBO at bay.
KeywordsPathogenesis of Parkinson’s disease Helicobacter Small intestinal bacterial overgrowth Blood leukocytes Natural-killer T-helper Neutrophils Hypokinesia Rigidity Tremor
Milestones in elucidating the aetiopathogenesis of Parkinson’s disease have been few and far between. We step back to consider the whole entity. Constipation featured in the original description. Frequency of defecation deviates from that of controls three decades before median age of diagnosis, and infrequent bowel movements are associated with subsequent diagnosis. Abnormal bowel function becomes more apparent post-diagnosis. In contrast peptic ulceration has prodromal excess and little-in-the-way of local aftermath. Morphological and neurochemical changes associated with Parkinson’s disease are found in the enteric nervous system of oesophagus, stomach, duodenum and small- and large-intestine, in coeliac and para-verebral sympathetic ganglia and dorsal vagal nuclei[6–11]. Mitochondrial dysmorphology is seen in duodenal enterocytes in idiopathic parkinsonism. This, if replicated in enteric neurones and/or myocytes, and associated with dysfunction, may provide a mechanism behind slow gastrointestinal transit.
What initiates and perpetuates slow transit? A viral primer cannot be excluded: enteroviruses infect via the gastrointestinal tract and can have neurological sequelae; jejunal denervation is seen with human immunodeficiency virus infection, which can cause parkinsonism. In mice, intranasal inoculation with H5N1 influenza virus resulted in passage from enteric and dorsal root ganglia to brain stem. Ascent from here left a trail of microglial activation and dopaminergic degeneration. Could Helicobacter pylori, the organism causally associated with peptic ulcer, affect transit? The H. pylori serum immunoblot antibody profile predicts abnormal bowel function in probands with idiopathic parkinsonism and their spouses. In the presence of an anti-urease-B band, there was a four-fold increase in the odds of having abnormal function, irrespective of subject-group and urea-breath-test evidence of current infection. With an outer-membrane protein antibody band, there was a six-fold decrement.
Probands with idiopathic parkinsonism, aged ≤72.5 years, are twice, and siblings of probands three-times, as likely as controls to be seropositive for H. pylori anti-urease antibody. As in peptic ulcer/gastric carcinoma, there is no birth-cohort effect in antibody titre in probands in contrast to controls. This is compatible with causality and/or progressive immunocompromise. In no disease where H. pylori is causal is it present in every case. In Western populations, follow-up of cohorts tends to demonstrate a loss of H. pylori. This is generally attributed to widespread use of antimicrobials and acid-suppressants: low eradication rates cumulate with repeated exposure. The mainstay of anti-parkinsonian therapy, dopaminergic precursors, agonists and promoters, act locally and centrally to protect against experimental ulcers[19–21]. Whether therapeutic doses of dopaminergic agents suppress Helicobacter has not been explored, but agonists have been used to prevent duodenal ulcer relapse. Danish population registers show increased prescription of Helicobacter eradication drugs in the 5 years prior to diagnosis of Parkinson’s disease, compatible with prodromal peptic ulcer. Persistent infection might explain aggressive parkinsonism. Subjective motor assessment is, indeed, worse, relative to time since diagnosis, in Japanese probands with H pylori. Parkinson’s disease has been linked to rural living and farm experience. A mortality study of 26 US states found increased proportional mortality from Parkinson’s disease among livestock, but not arable, farmers. Zoonotic-transmission of other gastric Helicobacters may contribute to the aetiopathogenesis.
H. pylori is an arbiter for progression of brady/hypokinesia in idiopathic parkinsonism[5, 27]. Improvement in gait, in the year following successful blinded-active anti-H. pylori treatment, was replicated by open-active following initial placebo-randomisation. Gait plateaued over the subsequent two years. Improvement was independent of whether patients were untreated or receiving stable anti-parkinsonian therapy (levodopa use excluded to avoid iatrogenic fluctuations in performance). The effect is not related to infection-load: eradicating H. pylori detected only by molecular microbiology on culture-negative biopsies (‘low-density’ colonisation) occasioned similar improvement. Marked deterioration accompanied the natural experiment of eradication failure, even where persistence was at low-density. All failures were anti-nuclear antibody (ANA) seropositive. Moreover, ANA-positivity marked a poorer response to ‘successful’ eradication, perhaps indicating persistent undetected infection. Furthermore, irrespective of anti-urease ELISA seropositivity, the H. pylori serum immunoblot antibody profile against pathogenicity markers (cytotoxicity-associated gene-A product, vacuolating toxin-A and urease-B) is predictive of risk, severity and deterioration of idiopathic parkinsonism. The underlying mechanism may be self-limiting auto-immunity. Autoimmunity is supported by the finding of HLA-DR risk loci[29, 30]. It may have a peripheral (eg. skeletal muscle and cardiac mitochondria) as well as basal ganglia targets[12, 14].
Improvement in brady/hypokinesia following H. pylori eradication was mirrored by an increase in objectively-measured flexor-rigidity: rigidity increased in year one post-eradication, plateaued over the subsequent two. In a case study, this increase in rigidity coincided with onset of hydrogen-breath-test positivity for small intestinal bacterial overgrowth (SIBO), rigidity decreasing on regaining negativity. Overgrowth may drive a subsidiary rigidity-associated pathogenic pathway, and be a relatively non-specific and dose-related player in perpetuating neuronal damage[14, 27]. A 54% prevalence of glucose-hydrogen-breath-test positivity for SIBO is reported in Parkinson’s disease, versus 8% in controls. Peripheral inflammation can evade or compromise the blood–brain barrier. Overgrowth could provide a source of inflammation over a wide surface area with a strong haematogenous signal to microglia, as well as an afferent vagal. (Gut-brain communication still occurs after vagotomy.)
Overgrowth is not an innocent bystander in the gastrointestinal tract: there is bloating and flatulence, and clouds of lysosomes are seen in duodenal enterocytes in relation to luminal bacteria (unpublished observation: A. Curry, SMD, RJD, IB). Long thin, often complex-branching, mitochondria are seen in duodenal enterocytes, rather than the protein arrays encapsulated by a double-membrane associated with H. pylori. Overgrowth could drive homocysteine production and increase utilisation of vitamin B12 (a co-factor in homocysteine detoxification). Neither hyperhomocysteinaemia (43%) nor serum B12 concentration, in idiopathic parkinsonism, is explained by Helicobacter status. Since slow transit predisposes to reflux of colonic flora into the small-intestine, SIBO is likely to begin as a secondary phenomenon, but it may exacerbate gastrointestinal neuronal damage.
Here, we use surveillance data to explore the relationship of different facets of idiopathic parkinsonism to peripheral immuno-inflammatory activation, in the light of presence/absence of Helicobacter infection or of SIBO. Do any relationships between facets and blood leukocyte subset counts stand in patients free from anti-parkinsonian drugs, and are they robust enough to defy fluctuations in performance consequent on levodopa therapy? This builds on our demonstration of biological gradients of objective measures of facets on two systemic markers of inflammation, serum cortisol and tumour-necrosis-factor-α[34, 35]. Reale et al. have subsequently shown gradients of global scores of function and motor impairment on peripheral blood mononuclear cell production of cyto/chemokines and expression of nuclear factor κB. The setting is that, compared with controls, there is a relative lymphopenia in idiopathic parkinsonism, with an upward shift in the proportional distribution of natural-killer cells, a downward in B-cells. T-helper and cytotoxic T-cell distributions are platykurtic (greater proportions than expected above and below reference ranges). Neutrophil counts tended to be higher. These findings were not attributable to anti-parkinsonian treatment. That of a relative lymphopenia confirmed previous smaller studies[37–40].
We also explore the relationship between Helicobacter and hydrogen-breath-test status in idiopathic parkinsonism. Gastric pathophysiology, conducive to peptic ulceration in the prodrome, might protect against colonisation of the small-intestine from above: gastrin secretion, evoked by antral-predominant gastritis, enhances the acid-barrier. Later, the barrier might be compromised by cytokine-mediated inhibition (local or central) of acid secretion or by corporal gastric atrophy. After presentation, any Helicobacter gastritis is characteristically mild, atrophy absent, but inflammation associated with SIBO, secondary to caeco-ileal reflux, could progressively inhibit acid, with suppression of Helicobacter (as seen with proton pump inhibitors).
Surveillance data: patients and setting
Inclusion and exclusion criteria for surveillance
Independently-living subjects with clinically-definitea idiopathic parkinsonism
Taking no or stable anti-parkinsonian medication
Caucasian with English as first language and living in UKb
Secondary parkinsonism, ‘parkinsonism-plus’ syndromes and other wider clinical entities
Other specific neurological condition
Inflammatory bowel disease or history of major gastrointestinal surgery
Other progressive or resolving disorders affecting physical ability or performance, or underlying incapacity sufficient to prevent assessments (e.g. use of walking aid)
Cardiovascular/respiratory symptoms during normal activities
UK MRC muscle strength score <4/5
Arthropathy, mucsulo-skeletal disorder or overt abnormalities of, or history of orthopaedic surgery to, joints of spine or lower limbs
Concurrent therapy with drugs which might be anti-dopaminergic or with hypnotics or sedatives
Recent change in life situation (e.g. bereavement or change in marital status/domicile)
Any assessments, blood sampling and breath-tests during acute inter-current illness were excluded from the analysis.
Clinical measurements of outcome
The following disease facets are monitored routinely at each visit:-
Brady/hypokinesia of gait
Distance-time gait indices are obtained using the shoestring device, a telemetric method suitable for routine assessment. Rested patients walk, “at your own speed” over 18 m in a 1.85 m wide corridor. A second walk follows 5 min rest. Stride-length and speed are analysed: values refer to ‘steady-state’, editing out any build-up at start of walk, tail-off at end. Stride-length usefully defines treatment effects and, when corrected for relevant demographic/anthropometric characteristics, discriminates well between those with and without diagnosed parkinsonism.
Upper limb rigidity
The supported forearm is moved horizontally, at a controlled velocity, through a 40° arc about the elbow. The side judged more rigid at the initial assessment is monitored throughout. Swing duration is 1.3 s, the pause between varying (1 to 3 s) to reduce the effect of anticipation. One minute’s acclimatization precedes 2½ min recording. A computer interface unit measures the torque required for passive displacement against position (sampling interval 25 ms). Mean torque for each extending and flexing swing is calculated, grand means taken for resistance to extension (termed ‘flexor-rigidity’) and to flexion (‘extensor-rigidity’). Greater rigidity in flexor than in extensor muscles is characteristic of parkinsonism.
Tremor of hands
A fixed camera films a plan-view of hands, resting semi-prone on the table in front of the seated patient. It records any tremor over one minute before, and during, stress from repeating-back, in reverse order, series of spoken random-numbers. The archive of surveillance videos was audited by an independent assessor, blind to date and treatment, using a visual-analogue scale for each recording condition. (Scale was from 0, the most intrusive tremor witnessed between-subject, to 100, no tremor). Differences in this assessor’s ratings from those of two others are small (mean 3–6 %) and not significant.
Instability at stance is measured by total angular displacement (sway) in the sagittal plane: patients stand at ease, with eyes open for 1 min, then closed for 3 min. Mean coronal foot-separation at mid-swing, using the shoestring device, provides an objective measure of stability during walking[46, 47].
Reaction time is measured as time taken to lift left or right index-finger from its touch-sensitive support. Two seconds before the imperative, an alerting signal does, or does not, warn whether left or right is to be lifted. ‘Cognitive efficiency’ is measured by the ratio, unwarned⁄warned reaction time.
Characteristics at start of surveillance period
Mean (95% data interval) (n= 51 )
65 (48, 81)
1.69 (1.51, 1.86)
76 (51, 102)
Time since diagnosis (years)
6.5 (4.4, 8.9)b
Anti-parkinsonian medication (no/yes)
Medication includes levodopa (no/yes) c
Blood cell counts
Total white cell count (109/l)
6.4 (3.9, 1.3)
3.8 (1.9, 7.3)
1.7 (0.9, 3.1)
Mononuclear cell subset (/μl) T-helper (CD4+)
810 (345, 1903)
392 (118, 1305)
170 (44, 657)
258 (94, 705)
Mean stride-length (mm)
1199 (795, 1602)
1.16 (0.68, 1.64)
Brady/hypokinesia scale (100 none, 0 worst)d
60 (55, 64)b
Mean torque to extend forearm (Nm x10-3)
589 (206, 1678)e
Mean torque to flex (Nm x10-3)
286 (98, 830)e
Ratio torque to extend/to flex
2.06 (0.80, 5.32)e
Mean tremor whilst seated (100 none, 0 worst)
92.3 (62.8, 100)b
100 (73.0, 100)
90 (50, 100)
Tremor during stance/walk scale (100 none, 0 worst)f
98.3 (83.3, 100)b
Mean body sway (°/min)
8.5 (3.7, 19.1)e
with eyes open
6.1 (2.2, 17.4)e
with eyes closed
9.2 (4.1, 2.4)e
Mean foot separation (mm)
190 (141, 256)
Simian posture scaleg
79 (61, 96)b
Coronal postural abnormality scaleh
85 (72, 97)b
Mean unwarned reaction time (ms)
518 (251, 1070)e
Mean warned reaction time (ms)
322 (154, 672)e
Mean arterial pressure
95 (66, 123)
Standing: mean over 3 min (mmHg)
Mean pulse rate
66 (48, 85)
Standing: mean over 3 min (/min)
75 (54, 95)
Previous Helicobacter eradication (no/yes)i
Helicobacter status (+ve /-ve)
Hydrogen breath-test status (+ve/-ve)
Rested supine and standing (immediate and at 1 and 3 min) blood pressure and pulse are measured. Body weight is measured unshod, without outer clothing. Unshod height is obtained with buttocks and heels against a wall, but the patient otherwise relaxed.
Blood cellular profile and autoantibody screen
Initially, a routine full blood count (XE2100, Sysmex UK Ltd., Wymbush UK), and mononuclear cell subset counts (FACSCalibur flow cytometer, Becton Dickinson, San Jose, California, USA, with four-colour fluorescent cell labelling using MultiTEST kit in TruCOUNT tubes) are obtained. The sum of the subset counts was validated by reference to ‘total lymphocytes’ in the full blood count. Serum is screened for ANA by indirect immunofluorescence using Hep2010 cells and rat stomach, kidney & liver composite tissue block (Euroimmun Biochip slides, Euroimmun UK, Pontypool, UK). Secondary antibodies are FITC-conjugated polyclonal rabbit anti-human IgG (Dako, Ely, UK). These standard immunological procedures are subject to the UK national external quality assurance scheme.
Initially, Helicobacter status is checked by 13C]urea-breath-test (INFAI Ltd., York, UK) and/or stool antigen (Oxoid, Basingstoke, UK) in all patients. Infection is routinely confirmed by endoscopic-biopsy (with written informed consent) for histopathology and/or culture, and, if culture negative, detection of H. pylori-specific DNA. Eradication therapy consists of one to two weeks’ proton pump inhibitor, plus two antimicrobials, selected according to in vitro sensitivities or with reference to clarithromycin susceptibility determined by molecular microbiology. Any history of intolerance is taken into account. Success is judged by the non-invasive tests at 6 weeks, confirmation by repeat endoscopic biopsy offered after at least 4 months.
Small intestinal bacterial overgrowth is screened for by the lactulose-hydrogen-breath-test in all patients, to monitor the need for/response to adequate fluid consumption and bulk/osmotic laxatives. A test consists of measuring breath-hydrogen concentration (Gastrolyser, Micro Medical Ltd., Rochester, UK) before and after (15-min intervals for 4 h) 25 G lactulose, following 24-h deprivation of dairy products (and medicinal lactulose) and a breakfast of 250 ml black tea/coffee or water. Status is defined by whether the meter manufacturer’s diagnostic cut–point (20 ppm increment) is exceeded by two consecutive readings within 2 h. A prolonged test, with non-absorbable substrate, was chosen because of potentially impaired gastric-empting and intestinal transit. Breath-hydrogen increases when lactulose reaches the colon, but false positives due to rapid oro-caecal transit are very unlikely in IP. Use of glucose risks missing distal SIBO, since it is absorbed proximally.
Observational data are used to describe patterns of association between disease facets and blood leukocyte subsets. False-positives are not anathema in the structured approach to hypothesis generation described below, false negatives are: adjustment for multiple comparisons is inappropriate.
The association between a cell count and each physiological/cognitive ‘outcome’ measure was assessed in isolation, using a linear mixed effects regression model with outcome measure as dependent variable and cell count as independent. Account was taken of dependencies due to the physiological outcome being measured longitudinally: a random intercept was generated for each patient by inclusion of a patient random effect in the regression model. In contrast, cell counts and potential demographic covariates were taken to be invariable and measured once at the beginning of surveillance.
The regression analysis was first targeted at a ‘core group’ of 38 probands receiving no anti-parkinsonian medication, or medication other than levodopa. Independent variables, for which evidence of an association could not be discounted in the single variable analysis (p<0.2), were included in multivariable linear mixed models. A backwards elimination process was used to remove, in turn, the least significant independent variable, until all remaining exhibited a statistically important association. Discarded variables were then each included separately into the resultant multivariable model to ensure that their lack of association remained true. Cellular associations with outcome of p-value ≤0.05 were considered to be ‘statistically significant’. A between-subject analysis, using the average outcome measure in each patient, was used to substantiate associations of outcome measure and cell count, but sizes of effect given refer to the longitudinal multivariable models. (Estimated regression lines shown are from analyses which include all values for a longitudinal outcome, although, for presentation purposes, the points are restricted to an average per person.) Surrogacy of inter-related outcome measures in explaining cellular associations was examined. Longitudinally-assessed Helicobacter and hydrogen-breath-test status was included in the final models to determine whether they might explain any associations between outcome and cell count. Multivariable models were fitted in the 17 ‘untreated’ patients alone and in the ‘entire’ group of 51 (including those receiving the short t½ medication, levodopa) to assess the consistency of associations in these contexts.
Similarly, single variable analysis and multivariable generalised linear mixed modelling were used to assess associations between hydrogen-breath-test status and cell counts.
A natural logarithmic transformation to approximate ‘Normality’ was performed on variables with a positively-skewed distribution. Assumptions of Normally distributed random effects and residuals were checked graphically using normal quantile plots. Combined scaled measurements obtained from videos had approximately Normal distributions.
Characteristics of patients with idiopathic parkinsonism
Table 2 gives baseline demographic and haematological data, outcome measures, and status with respect to Helicobacter and hydrogen-breath-test for the entire group.
Hydrogen-breath-test positivity was associated inversely with Helicobacter positivity (OR 0.20 (95% CI 0.04, 0.99), p=0.05). Hydrogen-breath-test positivity was unrelated to receipt of anti-parkinsonian medication other than levodopa, but directly associated with levodopa receipt (3.50 (1.01, 12.14), p=0.05).
Cellular association with breath-hydrogen
Cellular associations with clinical measurements
We present associations, meeting the set criteria, of leukocyte subsets implicated above (first natural-killer, second T-helper, third neutrophil), followed by any associations of other subsets studied (total lymphocyte, cytotoxic T-cell or B-cell), with:-
Associations with cell counts remained after adjustment for presence/absence of anti-parkinsonian medication in the core group (Additional file1: Table S3, Part a). Indeed, size and significance of effects were retained in the untreated group (Additional file1: Table S3, Part b). In the entire group, which included patients receiving levodopa, size of effect of natural-killer count on objective measures of brady/hypokinesia was similar to that in the core (Additional file1: Table S3, Part c), definition of effect on stride sharper in the core. Both size of effect and significance of the association between natural-killer count and flexor-rigidity were lost in the entire group. Those of T-helper count with both flexor- and extensor-rigidity were as strong as in the core. It should be noted that levodopa was not used as first-line treatment: stride tended to be shorter (by 128 (268, -12) mm, p=0.07) in those receiving it, rigidity was similar.
Mean arterial pressure
The natural-killer count association with pressure was not confounded by hydrogen-breath-test or Helicobacter status. Neither status had an additional effect on pressure. Size of effect of natural-killer count on pressure was independent of anti-parkinsonian medication in the core group, similar in the untreated and entire (Additional file2: Table S4, Parts a, b and c). However, in the untreated, it did not reach statistical significance.
The neutrophil association with tremor was not confounded by hydrogen-breath-test or Helicobacter status. However, Helicobacter positivity had an additional effect: tremor was less with positivity by 6.3 (0.5, 12.2) units (p=0.03). Size of effect of neutrophil count on tremor was independent of anti-parkinsonian medication in the core group, retained in the untreated and not masked in entire (Additional file3: Table S5, Parts a, b and c). However, in the untreated, it reached significance only at the 0.1 level.
No cellular association was seen with postural tremor while standing and walking, the neutrophil association with seated tremor remaining after including postural tremor in the model.
Single variable analysis did reveal a relationship of B-cell count to coronal posture rating (p=0.05): the higher the count, the better posture. Significance was similar (p=0.06) after correction for relevant covariates, time since diagnosis and weight. Rigidity held no surrogacy for coronal posture in the B-cell association, but its inclusion did have a small additional effect (p=0.001): the greater extensor-rigidity, the worse posture. Size of effect was retained in untreated (p=0.1), and entire (p=0.07) groups.
Neither hydrogen-breath-test nor Helicobacter status held surrogacy for the B-cell associations or had any direct effect on posture ratings. No cellular association was identified for objective assessments of standing body sway and ambulatory foot separation on single variable analysis.
Lack of association with psychomotor ability
There was no single variable association of reaction time (mean of unwarned and warned) or cognitive efficiency with any of the leukocyte subsets.
Overview of surveillance tools
Figure 8 gives an empirical overview of inter-relationships of the outcome measures between patients, using single-variable analysis.
Three cardinal signs, brady/hypokinesia, rigidity and tremor, are independent of each other under test conditions. The direct relationship between mean stride-length and free-walking-speed is close, as is that between tremor measured whilst seated and during stance/walk. That between flexor- and extensor-rigidity is not as close.
Tremor is weakly related to body sway: the worse the tremor, the greater the sway. Ambulatory coronal foot separation has a moderate association with brady- and hypo-kinesia: the narrower the separation, the worse gait. Simian posture rating is moderately related to brady- and hypo-kinesia, and to rigidity: bad posture goes with poorer gait and worse rigidity. Cognitive efficiency shows a weak direct association to stride and speed, reaction time a weak inverse association with speed: good psychomotor performance under test conditions is reflected in gait.
Supine mean arterial pressure stands independent of the other outcomes.
Helicobacter infection and small intestinal bacterial overgrowth in spouses
Spouses of 15 patients had requested screening for Helicobacter and SIBO: two-thirds (67 (exact binomial 95% CI 38, 88) %) were hydrogen-breath-test positive. One of these and two of the negatives were urea-breath-test positive.
Here we focus on the aftermath of H. pylori infection. In the gut/brain axis clinic, nearly three-quarters of the IP-patients surveyed had evidence of current or past infection on entry. Half had undergone successful eradication, a median of 3 years before. Two-thirds were lactulose-hydrogen-breath-test positive initially, four-fifths at some time during surveillance.
Our approach to aetiology/pathogenesis is to start from clinical clues. Statistical modelling of observational data is used to generate hypotheses. Having found subjective global clinical scores to be blunt instruments, we have embraced valid, sensitive, specific and reliable measures of disease facets. To avoid incorrect inferences, we endeavour to understand what is being measured, its variability and what influences it (i.e. confounding influences and bias), and explore effect modification (by interaction or directly). Use of objective measures brings economy of sample size. The pattern of cellular associates reported emphasises that facets may have different, non-coincident driving forces.
Bradford Hill wrote “The clear dose–response curve admits of a simple explanation”, causality. “Often the difficulty is to secure some satisfactory quantitative measure of the environment which will permit us explore this dose–response.” We identify biological gradients of facets of IP on blood leukocyte subset counts, and find the same group of subsets linked to SIBO. The simplest biologically plausible explanation is that the counts represent driving/ameliorating forces on the facets, and that SIBO is their source. The ‘Bradford Hill predicament’ is to secure which components and/or associates of SIBO might affect the inflammatory response. However, a complex causal pathway does not preclude interim clinical solutions. In IP, hydrogen-breath-test positivity indicates the need to assess faecal overload, particularly in caecum and ascending colon, and, where appropriate, to institute adequate fluid consumption and bulk/osmotic laxative therapy. Re-accumulation of overload is likely: enterokinetic agents have a potential role, particularly if the colon is dyskinetic with an element of retrograde propulsion.
Outcome associations with three leukocyte subsets withstood rigorous statistical criteria. Under test conditions, three facets were associated with natural-killer cell (CD16+56+) count: brady/hypokinesia, flexor-rigidity and higher mean arterial pressure. A higher count may be accompanied by higher serum cortisol with fluid retention, whereas (orthostatic) hypotension would be expected from ‘cold’ degeneration of sympathetic ganglia and brain stem noradrenergic nuclei. T-helper (CD4+) count was associated inversely with flexor-rigidity, neutrophil count inversely with tremor, as if mounting these immune responses were protective. Associations were independent of anti-parkinsonian medication.
In IP, SIBO has systemic consequence. Moreover, the above three out of the six leukocyte categories studied (total lymphocytes and neutrophils from full blood count; CD4+, CD8+, CD19+ and CD16+56+ mononuclear subsets) were associated with hydrogen-breath-test positivity, suggesting a mechanistic link. Hydrogen-breath-test status did not per se account for leukocyte associations with disease facets. Other measures of SIBO, a component or non-bacterial associate of SIBO, or imbalance in intestinal microbiota might. Hydrogen-breath-test positivity, like severity of IP manifestations, was related to higher CD16+56+ count and lower neutrophils, but, unlike severity, to a higher CD4+ count. The CD4+ subset includes regulatory T-cells which can inhibit effector mechanisms of natural-killer cells. A single rigidity-provoking taxon might evoke an increase in CD16+56+ count, a decrease in CD4+. For example, escape of a viral cause of slow transit may cause an increase in CD16+56+ count and, were it lymphotropic, suppression of CD4+. Alternatively, different components/associates of SIBO, with different cellular responses, might have opposite effects on rigidity.
Breath-hydrogen concentration from 2 to 4 h after lactulose reflected the earlier T-helper and natural-killer count associations, but not the neutrophil. Chronic bacterial overload may suppress neutrophils, overload in the more distal small-intestine not having the same capacity to suppress neutrophils as that in the proximal. A degree of immune tolerance to refluxed colonic microbiota might be acquired.
Definition of phenotype
The independence of the measures of brady/hypokinesia, rigidity, tremor and mean arterial pressure described provides a foundation on which to build a wider description of IP. Further measures should be complementary, not congruous.
It is remarkable that the relationship between natural-killer cells and brady/hypokinesia was robust enough to be captured by video assessment. However, the brady/hypokinesia scale becomes redundant in the face of rapid objective quantification. Focusing, in a formal protocol, on tremor whilst seated captured the neutrophil association, observing incidental tremor during walking did not. Although both simian and coronal posture ratings tended to capture a B-cell association, they were unrelated in single variable analysis. The association with simian posture persisted after large scale adjustment for rigidity (on the worse side) and brady/hypokinesia. Bilateral quantification of rigidity is a next step towards better definition of these B-cell associations. Coronal postural abnormality is a manifestation of disease asymmetry and compensation for this.
Assimilation of findings into potential pathogenic pathways
To consider causality in terms of single question steps, arising in unique linear order, denies the multi-step, multi-factorial nature of chronic disease. Not until a large number of observational and interventional findings have been assimilated will their position within the causal pathway become more certain. It cannot be assumed that disease facets will progress in parallel. The goal is stratification of pathogenic pathways into those central to disease initiation and the subsidiary, which may/may not be activated.
Summary of evidence that H. pylori infection and small intestinal bacterial overgrowth drive facets of parkinsonism
H. pylori infection
Double-blind, placebo-controlled, randomised efficacy study of eradication.
Differential effects with improvement in hypokinesia and worsening rigidity over year post-eradication and subsequent (2-year) plateau. Overall: net improvement.
(i) Detrimental effect of Helicobacter positivity on hypo- and bradykinesia (adjusted for natural-killer count) [Results: Cellular associations with clinical measurements].
(ii) Improvement in hypokinesia followed Helicobacter- eradication, but not antimicrobials given for other indications (i.e. indication specific).
Small intestinal bacterial overgrowth
(i) Same three leukocyte subset associated with hydrogen-breath-test positivity and facets (biological gradient of rigidity on natural killer and T-helper counts; brady/hypokinesia on natural killer; tremor on neutrophil) [Results: Cellular association with breath-hydrogen & Cellular associations with clinical measurements].
(ii) Increased rigidity followed antimicrobials for indications other than Helicobacter (i.e. not indication-specific), suggesting alteration in intestinal microbiota as a player.
The seemingly self-perpetuating microglial activation of IP may actually be a response to a continuous stimulus, commonly SIBO. This does not exclude exacerbation by other inflammatory stimuli. Patients frequently report transient worsening of parkinsonism with intercurrent illness/its treatment. Moreover, the adaptive immune response in substantia nigra in Parkinson’s disease, and the presence of peripheral immune cells (as well as Lewy bodies) in therapeutically-useful dopamine cell brain implants, fit with a peripheral immune process driving neuronal damage.
High prevalence of SIBO in IP has been shown by hydrogen-breath-tests using different substrates, lactulose and glucose. The slightly lower prevalence of positivity using the absorbable sugar may represent missed distal colonisation. We demonstrate an inverse association between hydrogen-breath-test and Helicobacter status. Since H. pylori is usually acquired in infancy, it is reasonable to postulate that any protection is by Helicobacter against SIBO. Whether the acid barrier and/or immune regulation determine such protection needs elucidation. The stability in anti-parkinsonian medication status over the surveillance period (median 2.8 years) may be a consequence of H. pylori eradication and attenuating SIBO by maintaining gastrointestinal transit.
Our usage of levodopa (as an adjuvant where functional impairment no longer responds adequately to other anti-parkinsonian medication) was associated with hydrogen-breath-test positivity. Meeting our indication for levodopa might coincide with worsening constipation, with more caeco-ileal reflux. Indeed, in a group of patients exposed only to levodopa combinations, hydrogen-breath-test positivity was linked to functional staging and severity, with no additional effect of levodopa dosage (average 800 mg/day).
Dopaminergic status as a determinant of immune response
It might be argued that the cellular associations with facets of parkinsonism simply reflect the influence of dopaminergic status on leukocytes. Dopamine has been implicated in immunoreguation[62, 63]. Its receptor densities differ between leucocyte subsets and exposure to dopamine affects the subsets differently. Overall, dopamine appears to increase natural-killer activity, and inhibit T-lymphocyte and neutrophil function. Thus, the leukocyte subset count associations with facets of IP do not fit with surrogacy of cell function for dopaminergic status, even were count assumed to represent function.
Crucial future directions
An association of non-H. pylori gastric Helicobacters with IP would have profound implications as to whether classical autoimmunity or pattern-recognition cross-reactivity is involved in the pathogenesis. Classical autoimmunity may be confined to particular strains within a bacterial species, whilst pattern recognition tends to be shared at genus level.
Whereas spouses of IP-patients have been used as controls, we find they are an important source of pathogenic clues[27, 44]. The prevalence of hydrogen-breath-test positivity in spouses was similar to that in IP-patients. Although the number tested was small, it is beyond the balance of probability that the prevalence in spouses is less than 38%. Replication would bring understanding the spouses’ predisposition to the fore in unravelling environmental causality.
More detailed observational work on slow transit, faecal impaction, gut microbiota, and understanding the immune response of the gut (which contains “70% of the immune system”) could identify new targets and strategies to influence disease progression. Cultural approaches to the gut microbiota are being superseded, as research tools, by metagenomic molecular microbiology. This has already defined patterns of stool microbiota (enterotypes) in the population and indicated changes in the spectrum in inflammatory bowel disease[66–68]. These changes include under representation of Gram positive anaerobes (a major component of faecal microbiota in health), which inhibit nuclear factor κB-related proinflammatory cytokine expression and can modulate effects of regulatory T-cells on tolerance and autoimmunity. The loss may be counterbalanced by increased representation of Gram negative bacteria expressing pro-inflammatory molecules, like lipopolysaccharide. Resort to aspiration, brushings or biopsy may be necessary to characterise proximal and distal overgrowth. Further work could, by defining the enterotype in IP with and without Helicobacter, home in on candidate drivers of systemic inflammatory activation leading to neuronal damage.
With respect to Hill’s classic attributes of a causal relationship, we have a coherent, hierarchical and biological-plausible scheme for the pathogenesis of idiopathic parkinsonism, with biological gradients and a proposed time sequence of events. Interpretation may be wrong in parts, due to real gaps in knowledge or lack of awareness of alternative explanations. However, the overall thrust gives new insights into potentially-remediable pathogenic influences. Hill’s attributes of a causal relationship also include strength of key associations expressed as relative risk or odds ratios, experimental evidence and analogies. These are well represented in the work-up. His attribute of consistency through repetition by different groups, in a range of locations selected to test robustness, needs addressing. That of specificity ‘in cause’ should be treated cautiously, since the scheme evokes more than one driving factor. Moreover, specificity may be masked, in a disease with a long prodrome, by classifying as ‘unaffected’ or true negatives those progressing towards the diagnostic threshold[17, 27, 44] and/or in whom the causal factor will first manifest as another condition (eg. prodromal peptic ulceration in IP).
Our grateful thanks go to Dr John Cazabon, Immunology Department, King’s College Hospital, for the cellular immunology The surveillance was funded through the Psychiatry Research Trust, London, which received grants from and the Cecil Pilkington Charitable Trust, the Cyril Corden Trust, and donations from Brian Newman & Louise Barton Barclays Corporate Social Responsibility Ambassador, Nicholas Smith, co-ordinated a fundraising program with the help of patients and carers None of the funding sources were involved in the work.
- Parkinson J: An Essay on the Shaking Palsy. Sherwood Neely and Jones, London; 1817.
- Charlett A, Dobbs RJ, Weller C, Dobbs SM: Stasis in the gut: the source of xenobiotic in idiopathic parkinsonism. Eur J Clin Pharmacol 1997, 52 (suppl): 168.
- Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW: Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001, 57: 456-462. 10.1212/WNL.57.3.456.View ArticlePubMed
- Strang RR: The association of gastro-duodenal ulceration with Parkinson’s disease. Med J Austr 1965, 52: 842-843.
- Dobbs SM, Dobbs RJ, Weller C, Charlett A, Bjarnason IT, Lawson AJ, Letley D, Harbin L, Price AB, Ibrahim MA, Oxlade NL, Bowthorpe J, Leckstroem D, Smee C, Plant JM, Peterson DW: Differential effect of Helicobacter pylori eradication on time trends in brady/hypokinesia and rigidity in idiopathic parkinsonism. Report on completion of a randomised, double-blind, placebo-controlled efficacy study. Helicobacter 2010, 15: 279-294. 10.1111/j.1523-5378.2010.00768.x.PubMed CentralView ArticlePubMed
- Qualman SJ, Haupt HM, Yang P, Hamilton SR: Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Gastroenterology 1984, 87: 848-856.PubMed
- Kupsky WJ, Grimes MM, Sweeting J, Bectsch R, Cote LJ: Parkinson’s disease and megacolon: Hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987, 37: 1253-1255. 10.1212/WNL.37.7.1253.View ArticlePubMed
- Wakabayashi K, Takahashi H, Ohama E, Ikuta F: Parkinson’s disease: an immunohistochemical study of Lewy-body containing neurons in the enteric nervous system. Acta Neuropathol 1990, 79: 581-583. 10.1007/BF00294234.View ArticlePubMed
- Singaram C, Ashraf W, Gaumnitz EA, Torbey C, Sengupta A, Pfeiffer R, Quigley EM: Dopaminergic defect of enteric nervous system in Parkinson’s disease patients with chronic constipation. Lancet 1995, 346: 861-864. 10.1016/S0140-6736(95)92707-7.View ArticlePubMed
- Braak H, Del Tredici K, Rüb U, De Vos RAI, Jansen Steur ENH, Braak E: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003, 24: 197-211. 10.1016/S0197-4580(02)00065-9.View ArticlePubMed
- Braak H, de Vos RAI, Bohl J, Del Tredici K: Gastric a-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 2006, 396: 67-72. 10.1016/j.neulet.2005.11.012.View ArticlePubMed
- Ellis D, Dobbs RJ, Dobbs S, Curry A, Bjarnason I, Williams J, McCrossan MV, Weller C, Charlett A: Duodenal enterocyte mitochondrial involvement and abnormal bowel function in idiopathic parkinsonism. In New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2007. Edited by: Hanin I, Windisch M, Poewe W, Bologna FA. Medimond Srl; 2007:269-272.
- Lang AE, Lozano AM: Parkinson’s disease. New Eng J Med 1998, 339: 1044-1053. 10.1056/NEJM199810083391506.View ArticlePubMed
- Dobbs RJ, Dobbs SM, Weller C, Charlett A, Bjarnason IT, Curry A, Ellis DS, Ibrahim MA, McCrossan MV, O'Donohue J, Owen RJ, Oxlade NL, Price AB, Sanderson JD, Sudhanva M, Williams J: Helicobacter hypothesis for idiopathic parkinsonism: before and beyond. Helicobacter 2008, 13: 309-322. 10.1111/j.1523-5378.2008.00622.x.View ArticlePubMed
- Jang H, Boltz D, Strum-Ramirez K, Shepherd KR, Jiao Y, Webster R, Smeyne RJ: Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci USA 2009, 106: 14063-14068. 10.1073/pnas.0900096106.PubMed CentralView ArticlePubMed
- Dobbs RJ, Charlett A, Dobbs SM, Weller C, Peterson DW: Parkinsonism: differential age-trend in Helicobacter pylori antibody. Aliment Pharmacol Ther 2000, 14: 1199-1205. 10.1046/j.1365-2036.2000.00815.x.View ArticlePubMed
- Charlett A, Dobbs RJ, Dobbs SM, Weller C, Brady P, Peterson DW: Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome. Acta Neurol Scand 1999, 99: 26-35. 10.1111/j.1600-0447.1999.tb05381.x.View ArticlePubMed
- Wang TC, Fox JG: Helicobacter pylori and gastric cancer: Koch's postulates fulfilled? Gastroenterology 1998, 115: 642-648. 10.1016/S0016-5085(98)70143-X.View Article
- Szabo S: Dopamine disorder in duodenal ulceration. Lancet 1979, ii: 880-882.View Article
- Glavin GB: Activity of selective dopamine DA1 and DA2 agonists and antagonists on experimental gastric lesions and gastric acid secretion. J Pharmacol Exp Ther 1989, 251: 726-723.PubMed
- Xing L, Washington J, Seaton J, Kauffman G: Monoamine oxidase B inhibition reduces gastric mucosal blood flow, basal acid secretion, and cold water restraint-induced gastric mucosal injury in rats. Dig Dis Sci 1990, 35: 61-65. 10.1007/BF01537224.View ArticlePubMed
- Sikiric P, Rotkvic I, Mise S, Petek M, Rucman R, Seiwerth S, Zjacic-Rotkvic V, Duvnjak M, Jagic V, Suchanek E: Dopamine agonists prevent duodenal ulcer relapse. Dig Dis Sci 1991, 36: 905-910. 10.1007/BF01297139.View ArticlePubMed
- Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B: Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol 2012, 19: 864-869. 10.1111/j.1468-1331.2011.03643.x.PubMed CentralView ArticlePubMed
- Tsuboi Y, Yamada T: Prevalence of Helicobacter pylori infection among patients with Parkinson’s disease: impact on clinical manifestations. Mov Disord 2008, 23 (suppl 1): S291.
- Wirdefeldt K, Adami H-O, Cole P, Trichopoulos D, Mandel J: Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 2011, 26: S1-58.View ArticlePubMed
- Lee E, Burnett CA, Lalich N, Cameron LL, Sestito JP: Proportionate mortality of crop and livestock farmers in the United States, 1984–1993. Am J Ind Med 2002, 42: 410-420. 10.1002/ajim.10131.View ArticlePubMed
- Charlett A, Dobbs RJ, Dobbs SM, Weller C, Weller C, Ibrahim MA, Dew T, Sherwood R, Oxlade NL, Plant JM, Bowthorpe J, Lawson AJ, Curry A, Peterson DW, Bjarnason IT: Blood profile holds clues to role of infection in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in established disease. Gut Pathogens 2009, 1: 2-1 1186/1757-4749-1-2.View Article
- Weller C, Oxlade NL, Dobbs SM, Dobbs RJ, Peterson DW, Bjarnason IT: Role of Chronic Infection and Inflammation in the Gastrointestinal Tract in the Aetiology and Pathogenesis of Idiopathic Parkinsonism Part 3: Predicted probability and gradients of severity of idiopathic parkinsonism based on H pylori antibody profile. Helicobacter 2005, 10: 288-297. 10.1111/j.1523-5378.2005.00329.x.View ArticlePubMed
- Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott W, Nutt J, Factor SA, Payami H: Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet 2010, 42: 781-785. 10.1038/ng.642.PubMed CentralView ArticlePubMed
- International Parkinson Disease Genetics Consortium: Imputation of sequence variants for identification of genetic risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377: 641-649.View Article
- Gabrielli M, Bonazzi P, Scarpellini E, Bendia E, Lauritano EC, Fasano A, Ceravolo MG, Capecci M, Rita Bentivoglio A, Provinciali L, Tonali PA, Gasbarrini A: Prevalance of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord 2011, 26: 889-892. 10.1002/mds.23566.View ArticlePubMed
- Watkins AD: Perceptions, emotions and immunity: An integrated homeostatic network. Q J Med 1995, 88: 283-294.
- Bercik P, Verdu EF, Foster JA, Macri J, Potter M, Huang X, Malinowski P, Jackson W, Blennerhassett P, Neufeld KA, Khan WI LJ, Corthesy-Theulaz I, Cherbut C, Bergonzelli GE, Collins SM: Chronic gastrointestinal inflammation induces anxiety-like behaviour and alters central nervous system biochemistry in mice. Gastroenterology 2010, 139: 2102-2112. 10.1053/j.gastro.2010.06.063.View ArticlePubMed
- Charlett A, Dobbs RJ, Purkiss AG, Weller C, Peterson DW, Dobbs SM: Cortisol is higher in parkinsonism and associated with gait deficit. Acta Neurol Scand 1998, 97: 77-85.View ArticlePubMed
- Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW: Association of circulating TNF-a and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999, 100: 34-41. 10.1111/j.1600-0404.1999.tb00721.x.View ArticlePubMed
- Reale M, Iarlori C, Thomas A: Peripheral cytokines profile in Parkinson’s disease. Brain Behaviour Immunity 2009, 23: 55-63. 10.1016/j.bbi.2008.07.003.View Article
- Martilla RJ, Eskola J, Päivärinta M, Rinne UK: Immune functions in Parkinson’s disease. Adv Neurol 1984, 40: 315-323.
- Bas J, Calopa M, Mestre M, Molleví DG, Cutillas B, Ambrosio S, Buendia E: Lymphocyte populations in Parkinson’s disease and in rat models of parkinsonism. J Neuroimmunol 2001, 113: 146-152. 10.1016/S0165-5728(00)00422-7.View ArticlePubMed
- Hisanaga K, Asagi M, Itoyama Y, Iwasaki Y: Increase in peripheral CD4 Bright+ CD8 Dull+ T cells in Parkinson’s disease. Arch Neurol 2001, 58: 1580-1583. 10.1001/archneur.58.10.1580.View ArticlePubMed
- Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T: Alterations of T-lymphocyte populations in Parkinson disease Parkinsonism. Relat Disord 2005, 11: 493-498. 10.1016/j.parkreldis.2005.07.005.View Article
- El-Omar EM: The importance of interleukin 1ß in Helicobacter pylori associated disease. Gut 2001, 48: 743-747. 10.1136/gut.48.6.743.PubMed CentralView ArticlePubMed
- Calne DB, Snow BJ, Lee C: Criteria for diagnosing Parkinson’s Disease. Ann Neurol 1992, 32 (suppl): S125-S127.View ArticlePubMed
- Weller C, O'Neill CJA, Charlett A, Bowes SG, Purkiss A, Nicholson PW, Dobbs RJ, Dobbs SM: Defining small differences in efficacy between anti-Parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor. Br J Clin Pharmacol 1993, 35: 379-385. 10.1111/j.1365-2125.1993.tb04154.x.PubMed CentralView ArticlePubMed
- Kirollos C, O'Neill CJA, Dobbs RJ, Charlett A, Bowes SG, Purkiss AG, Hunt WB, Dobbs SM: Quantification of the cardinal signs of Parkinsonism and of associated disability in spouses of sufferers. Age Ageing 1993, 22: 20-26. 10.1093/ageing/22.1.20.View ArticlePubMed
- Kirollos C, Charlett A, Bowes SG, Purkiss AG, O'Neill CJ, Weller C, Dickins J, Faulkner G, Nicholson PW, Hunt WB, Dobbs RJ, Dobbs SM: Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism. Eur J Clin Pharmacol 1996, 50: 7-18. 10.1007/s002280050062.View ArticlePubMed
- Charlett A, Weller C, Dobbs SM, Dobbs RJ: Breadth of base whilst walking: effect of ageing and parkinsonism. Age Ageing 1998, 27: 49-54.View ArticlePubMed
- Weller C, Humphrey SJE, Kirollos C, Bowes SG, Charlett A, Dobbs SM, Dobbs RJ: Gait on a shoestring: falls and foot separation in parkinsonism. Age Ageing 1992, 21: 242-244. 10.1093/ageing/21.4.242.View ArticlePubMed
- Dobbs RJ, Bowes SG, Charlett A, Henley M, Frith C, Dickins J, Dobbs SM: Hypothesis: The bradyphrenia of Parkinsonism is a nosological entity. Acta Neurol Scand 1993, 87: 255-261. 10.1111/j.1600-0404.1993.tb05504.x.View ArticlePubMed
- Bland JM, Altman DG: Statistics notes: Cronbach’s alpha. Br Med J 1997, 314: 572-10.1136/bmj.314.7080.572.View Article
- Nunnally JC, Bernstein IH: Psychometric Theory.3rd edition. McGraw-Hill, New York; 1997:265.
- Rhodes JM, Middleton P, Jewell DP: The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial over-growth. Scand J Gastroenterol 1979, 14: 333-336. 10.3109/00365527909179892.View ArticlePubMed
- Pfeiffer RF: Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 2003, 2: 107-116. 10.1016/S1474-4422(03)00307-7.View ArticlePubMed
- Yu D, Cheeseman F, Vanner S: Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011, 60: 334-334. 10.1136/gut.2009.205476.View ArticlePubMed
- Abu-Shanab A, Quigley EMM: Diagnosis of small intestinal bacterial overgrowth: the challenges persist. Expert Rev Gastroenterol Hepatol 2009, 3: 77-87. 10.1586/17474188.8.131.52.View ArticlePubMed
- Bowes SG, Dobbs RJ, Henley M, Charlett A, O'Neill CJ, Nicholson PW, Purkiss AG, Weller C, Dobbs SM: Objective evidence for tolerance, against a back-ground of improvement during maintenance therapy with controlled release levodopa/carbidopa. Eur J Clin Pharmacol 1992, 43: 483-489. 10.1007/BF02285089.View ArticlePubMed
- Hill AB: The environment and disease: association or causation? Proc Roy Soc Med 1965, 58: 295-330.PubMed CentralPubMed
- Frampton JE: Prucalopride Drugs. 2009, 69: 2463-2476.
- Huang X, Reynolds AD, Mosley RE, Gendelman HE: CD 4+ T cells in the pathobiology of neurodegenerative disorders. J Neuroimmunol 2009, 211: 3-15. 10.1016/j.jneuroim.2009.04.006.PubMed CentralView ArticlePubMed
- Pfeiffer RF: Neuroinflammation and Parkinson disease: The silent battleground. Neurology 2009, 73: 1434-1435. 10.1212/WNL.0b013e3181c2f07d.View ArticlePubMed
- Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM: A possible role for humoral immunity in the pathogenesis of Parkinson’s disease. Brain 2005, 28: 2665-2674.View Article
- Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB: Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord 2008, 23: 2303-2306. 10.1002/mds.22369.View ArticlePubMed
- Basu S, Dasgupta PS: Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol 2000, 102: 113-124. 10.1016/S0165-5728(99)00176-9.View ArticlePubMed
- Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S: The immunoregulatory role of dopamine: an update. Brain Behaviour Immunity 2010, 24: 525-528. 10.1016/j.bbi.2009.10.015.View Article
- Dobbs RJ, Dobbs SM, Weller C, Bjarnason IT, Oxlade NL, Charlett A, Al-Janabi MA, Kerwin RW, Mahler RF, Price AB: Role of chronic infection and inflammation in the gastrointestinal tract in the aetiology and pathogenesis of idiopathic Parkinsonism. Part 1: eradication of Helicobacter in the Cachexia of Idiopathic Parkinsonism. Helicobacter 2005, 10: 267-275. 10.1111/j.1523-5378.2005.00331.x.View ArticlePubMed
- MacDonald TT: The gut is still the biggest lymphoid organ in the body. Mucosal Immunol 2011, 1: 246-247.
- Manichanh C, Rigottier-Gois L, Bonnaud E: Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 2006, 55: 205-211. 10.1136/gut.2005.073817.PubMed CentralView ArticlePubMed
- Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto J-M, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P: A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464: 59-65. 10.1038/nature08821.PubMed CentralView ArticlePubMed
- Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto J-M, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T: Enterotypes of the human gut microbiome. Nature 2011, 473: 174-178. 10.1038/nature09944.PubMed CentralView ArticlePubMed
- Atarashi K, Honda K: Microbiota in autoimmunity and tolerance. Current Opin Immunol 2011, 23: 761-768. 10.1016/j.coi.2011.11.002.View Article
- Calne DB: Parkinson’s disease is not one disease. Parkinsonism Relat Disord 2001, 7: 3-7.View Article
- Beck AT, Beamesderfer A: Assessment of depression: the depression inventory. Psychological Measurements in Psychopharmacology Volume 7: Modern Problems in Psychiatry. Edited by: Basel PT.: Karger; 1974:151-159.
- Folstein MF, Folstein SE, McHugh PR: Mini-mental state a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1995, 12: 189-198.View Article
- Dobbs SM, Charlett A, Dobbs RJ, Weller C, Lawson AJ, Iguodala O, Bowthorpe J, Taylor D, Bjarnason I: Helicobacter and small intestinal bacterial overgrowth: consecutive players in the pathogenesis of idiopathic parkinsonism. Helicobacter 2011, 16 (Suppl. 1): 128.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.